A Agilent Technologies Inc.

Agilent Technologies CTO Darlene Solomon Elected to National Academy of Engineering

Agilent Technologies Inc. (NYSE: A) today announced that Dr. Darlene Solomon, Agilent senior vice president and chief technology officer, has been elected to the National Academy of Engineering – considered among the highest professional distinctions accorded to an engineer or technologist.

Solomon was elected for her “leadership in the development of innovative nucleic-acid and microfluidic products,” the academy said. These are foundational innovations, developed by scientists and engineers in Agilent Laboratories, that contribute to Agilent products at the leading edge of biomolecular research – especially toward the advancement of precision medicine.

NAE is an independent, nonprofit institution that advises the federal government on issues related to engineering and technology. Founded in 1964, it elects as members those who have made outstanding contributions to engineering research, practice or education.

“NAE is the world’s pre-eminent society of engineers, and becoming a member selected by one’s peers is a very special recognition of contribution,” Solomon said. “I am deeply honored to be part of this distinguished academy. I am also grateful to Agilent for its vision that includes the strength of pairing science and engineering principles in ways that help improve lives.”

Solomon’s responsibilities include Agilent Labs, with a focus on life sciences and diagnostics; University Relations; and the Early Stage Partnership Program. She works closely with Agilent CEO Mike McMullen as a member of the executive staff, and with Agilent’s businesses to define the company’s technology strategy and R&D priorities.

McMullen offered his congratulations, praising Solomon as “an excellent choice” for NAE membership. “She is a true visionary who understands the power of science built on engineering fundamentals,” McMullen said.

Solomon and the other newly elected members will be formally inducted during a ceremony at the NAE’s annual meeting in Washington, D.C., on Oct. 8.

About Darlene Solomon

Darlene Solomon, Ph.D.

Senior Vice President, Agilent

Chief Technology Officer

Darlene Solomon is senior vice president and chief technology officer for Agilent Technologies. She leads Agilent Labs with a focus on life sciences and diagnostics, and she manages the company’s university relations, corporate library and external venture investments. In her leadership role, she works closely with Agilent’s businesses to define the company’s technology strategy and R&D priorities.

Solomon brings extensive experience in R&D and management to her current leadership role at Agilent. She joined Hewlett-Packard Laboratories in 1984 as a member of the technical staff, subsequently holding a variety of research and management positions there, including R&D manager for the Chemical and Biological Systems Department. She joined Agilent when the company was formed in 1999 with a dual role as director of the Life Sciences Technologies Laboratory within Agilent Laboratories and as senior director, research and development/technology, for Agilent's Life Sciences and Chemical Analysis business. Prior to being named to her current post, Solomon was vice president and director of Agilent Laboratories.

Solomon received her bachelor's degree in chemistry from Stanford University and a doctorate in bioinorganic chemistry from the Massachusetts Institute of Technology, and she completed Stanford University’s Executive Development Program. In recognition of her career accomplishments, Solomon was elected to the National Academy of Engineering in 2017. She was also inducted into the Women in Technology International's Hall of Fame in 2001, received the YWCA Tribute to Women and Industry Award in 2004, and was named to Diversity Journal’s Women Worth Watching in 2007 and Corporate Board Member’s 50 Top Women in Technology in 2008.

Solomon serves on multiple academic and government advisory and review boards, including current and past appointments to the National Academies’ Board on Chemical Sciences and Technology, Visiting Committee on Advanced Technology of the National Institutes of Standards and Technology (2010-16), Stanford University Interdisciplinary Biosciences Advisory Council, UC Berkeley’s College of Engineering, Bay Area Science and Innovation Consortium (BASIC), and A-STAR Board for Singapore Economic Development (2004-10).

Download Darlene Solomon's biography in Word format.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.

EN
27/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch